Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Australia
Nucleus Network ( Site 0002), Brisbane, Queensland Nucleus Network ( Site 0001), Melbourne, Victoria